The innovative cobas® HIV-1 dual-target assay enables accurate detection and quantification even in the presence of drug-induced mutations, driving better decisions for a positive impact on patients’ lives.
The innovative cobas® HIV-1 dual-target assay enables accurate detection and quantification even in the presence of drug-induced mutations, driving better decisions for a positive impact on patients’ lives.
References
1. Loeb LA et al. Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc Natl Acad Sci U S A. 1999; 96: 1492–1497.
2. [15] Wainberg MA et al. The development of novel HIV integrase inhibitors and the problem of drug resistance. Curr Opin Virol. 2012; 2: 656-662.
3. Data on File with Roche Diagnostics, September 2015.
4. Reference Drug Manufacturer Package Inserts.
5. DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Last Updated July 14, 2016. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed 2/1/2017.
6 .J. Clin, Microbology. Damond F et al. (2010).
7. J Clin Microbiol. Wojewoda CM et al. (2013).
8. HIV in the United States: At A Glance. https://www.cdc.gov/hiv/statistics/overview/ataglance.html accessed on 1-26-2018.
References:
9. Roche cobas HIV-1 Package Insert (w/ Low Volume) (v3.0, pg. 13)
